It's curious that they took away the primary endpoint from the 14 week trial, CDR-COA and added a different cognitive measure as a secondary endpoint, MoCA.
Hopefully it's because the results for CDR-COA were promising and they don't want to mess with that over 48 weeks (ie they got the effect they feel they need and figure why not try a different measure), rather than they weren't good at all and they're abandoning one cognitive measure for another. Either way, if the secondary measures are impressive, the SP should go up significantly. It won't be like a phase 3 primary endpoint failure, as more trials were always the reasonable, optimistic expectation, and regular PD is a bigger market than PDD (I know, I know, ALZ inferences).
News 
Market Data 
Discover 
AI
